Prostate Cancer

Data from phase II study evaluating Quadramet with docetaxel reported

Published in Women's Health Weekly, June 16th, 2005

Cytogen Corp. (CYTO), a product-driven biopharmaceutical company, announced the publication of data from a phase II study of Quadramet (samarium Sm-153 lexidronam injection), the company's flagship product, in combination with docetaxel (Taxotere, Aventis Pharmaceuticals, a member of the sanofi-aventis Group) for the treatment of patients with hormone refractory prostate cancer.

The published abstract is part of the proceedings at the 2005 American Society of Clinical Oncology annual meeting held May 13-17, 2005, in Orlando, Florida. The lead investigator was Anders Widmark, MD, PhD, professor, department of oncology, Umea University, Sweden.

"Two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry